www.naturalnano.com) is sorry for the..." /> www.naturalnano.com) is sorry for the..." /> www.naturalnano.com) is sorry for the..." />

Correction: Enhanced Targeting of Cancer Cells for Capture Through the Use of NaturalNano's Halloysite Nanotubes Report to be Presented This Thursday the 13th at The Biomedical Engineering Society


ROCHESTER, N.Y., Oct. 11, 2011 (GLOBE NEWSWIRE) -- NaturalNano, Inc. (OTCBB:NNAN) (http://www..naturalnano.com/">www.naturalnano.com) is sorry for the confusion caused by yesterday's release. Dr. Michael King's lab of Cornell University will present their recent work at The Biomedical Engineering Society Annual Meeting (http://www.bmes.org/aws/BMES/pt/sp/meetings">http://www.bmes.org/aws/BMES/pt/sp/meetings) at 11 am this Thursday, October 13th, not Monday, October 10th, 2011.

The title of their presentation is "Halloysite Nanotube Coating Applications for Enhanced Capture and Reprogramming of Circulating Tumor Cells."

About NaturalNano, Inc.

NaturalNano, Inc. (OTCBB:NNAN) is a materials science company focused on developing and commercializing advanced nanocomposites. The Company is focused on additive technologies and processes, including its proprietary Pleximer that adds value to industrial polymers, plastics and composites. NaturalNano holds and/or licenses 20 patents and applications relating to Halloysite, as well as proprietary know-how for its extraction and separation processes, compositions, and derivatives. http://www.naturalnano.com/">www.naturalnano.com

Cautionary Statement Regarding Forward-Looking Statements: Contains forward-looking statements regarding future events and future performance that involve risks and uncertainties that could materially affect actual results. This information is qualified in its entirety by cautionary statements and risk factors disclosure contained in certain of NaturalNano's filings with the Securities and Exchange Commission. The most recent annual reports on Form 10-K and quarterly reports on Form 10-Q filed by NaturalNano provide information about these factors, which may be revised or supplemented in future reports to the SEC on those forms or on Form 8-K. We caution investors not to place undue reliance on forward-looking statements, and we do not undertake any obligation to update or otherwise revise any forward-looking statements, whether as a result of new information, future events, or other such factors that affect the subject of these statements, except where expressly required by law.



            

Contact Data